Along with the many successes of CPIs in clinical trials, it has become clear that tumor-infiltrating antigen-specific effector CD8+ T cell responses are essential for successful CPI therapy, and that to further improve responses, there is a need for combinatorial treatments, such as vaccines, that can activate and mobilize tumor-specific CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.